NSCLC Japanese patients harboring activating EGFR mutations and radiologically progressed on EGFR-TKI treatment as the first- or second-line setting, were classified into two groups: 39 patients received continuous EGFR-TKI and 25 patients switched to chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.